Panicein Compounds Inhibit Patched Receptor Efflux
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges due to chemotherapy resistance in cancer cells, particularly those expressing the Patched receptor, which contributes to drug efflux and resistance to chemotherapeutic agents, with no available antagonists for the Patched receptor.
Innovation Solution
The use of panicein compounds, such as Panicein C, Panicein B3, and Panicein A hydroquinone, to inhibit Patched receptor drug efflux activity, thereby enhancing the effectiveness of chemotherapeutic agents and reducing cancer metastasis and recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used to treat cancer, then cancer cell proliferation is inhibited, but chemotherapy resistance develops due to Patched receptor-mediated drug efflux
Solution Approach 1:
The patent uses panicein compounds as intermediary substances that bind to the Patched receptor and displace chemotherapeutic agents from the efflux pump binding site. This mediator approach allows the chemotherapeutic drug to remain active while blocking the efflux mechanism, thereby reversing resistance without requiring new chemotherapy agents.
Solution Approach 2:
The patent changes the binding parameters of the Patched receptor by introducing panicein compounds with specific molecular structures (formula I) that have higher affinity for the receptor's drug binding site. This parameter change in binding affinity prevents chemotherapeutic agents from being effluxed, thereby maintaining their cytotoxic effectiveness.
2Reliability
If the Patched receptor is targeted to inhibit drug efflux, then chemotherapy resistance is reduced, but no specific antagonists are available
Solution Approach 1:
The patent employs panicein compounds that can be extracted from natural sources (marine sponges) or synthesized relatively simply compared to developing entirely new receptor-targeted biologics. These small molecule compounds serve as disposable antagonists that can be administered to block Patched-mediated efflux without requiring complex manufacturing processes.
3Reliability
If panicein compounds are used to inhibit Patched receptor efflux activity, then drug efflux is blocked and chemotherapy effectiveness is enhanced, but the mechanism of action must be validated
Solution Approach 1:
The patent employs multiple feedback mechanisms to validate the proposed mode of action: (1) measuring intracellular accumulation of chemotherapeutic agents as direct feedback of efflux inhibition, (2) assessing cytotoxicity enhancement as functional feedback, and (3) using yeast models with controlled Patched expression to provide systematic feedback on structure-activity relationships.
Data Source
Figure 1
Figure 2A~2C
Figure 2D
AI summary
The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.